GAUSS-3: Evolocumab Outperforms Ezetimibe in Certain Statin-Intolerant Patients
Evolocumab significantly reduced LDL-C at 24 weeks in patients with statin intolerance related to adverse events compared with ezetimibe.
Cholesterol
ACCELERATE: Evacetrapib Does Not Reduce Major CV Events in High-Risk Patients
Evacetrapib did lower low-density lipoprotein cholesterol in high vascular risk patients, but did not reduce major cardiovascular events.
More Statin Use Among Patients of Puerto Rican and Dominican Backgrounds
In patients who were at high risk for cardiovascular disease, 25% of those from Puerto Rican and Dominican backgrounds used statins and less than half used aspirin.
Frequent Incidence of Familial Hypercholesterolemia Increases Heart Disease Risk
Researchers concluded that approximately 834 500 Americans have this inherited condition.
Practicing Traditional Chinese Exercises May Improve Cardiovascular Health
Tai chi, qigong, and other traditional Chinese exercises appeared to improve quality of life and reduce depression in patients with cardiovascular disease.
Statins: Beyond Treatment for Low-Density Lipoprotein Cholesterol
In metabolomic profiling study, statins were found to affect more extensive lipid changes beyond low-density lipoprotein cholesterol.
Higher Triglyceride Levels Associated With Increased Mortality in Coronary Heart Disease
Coronary heart disease patients with high triglyceride levels have an increased 22-year mortality risk, independent of high-density lipoprotein cholesterol levels.
Metabolic Syndrome Declines in US Adolescents
National Health and Nutrition Examination Survey data from 1999 to 2012 were analyzed and revealed a decline in metabolic syndrome in US adolescents (aged 12 to 19 years).
LDL-C Target Levels More Likely Achieved With High or Immediate-Potency Statins
Target low-density lipoprotein cholesterol levels were more likely achieved in cardiology and endocrinology departments and at higher potency levels.
- Loading...
Loading...
Loading... 
Loading...